Eupraxia Pharmaceuticals vs Satellos Bioscience
EPRX and MSLE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EPRX | MSLE |
|---|---|---|
| Size and price | ||
| Share price | $8.15 | $6.63 |
| Change, 1 year | 23.5% | 10.4% |
| Change, 5 years | 254% | −45.5% |
| Beta (5Y) | −0.02 | 3.41 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Profitability | ||
| Return on equity | −66.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 15.12 (better) | 7.77 |
| Piotroski F-score | 4 | – |
| Ownership | ||
| Held by institutions | 41.1% | 49.7% |
| Held by insiders | 9.7% | 0.00% |
| Short interest, % of float | 11.5% | 0.82% |
Go deeper
- EPRX stock overview
- EPRX income statement
- EPRX valuation and score
- MSLE stock overview
- MSLE income statement
- MSLE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.